We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cipher Pharmaceuticals Inc (CPH) NPV

Sell:14.80 CAD Buy:15.57 CAD Change: 0.20 CAD (1.30%)
Market closed |  Prices as at close on 1 November 2024 | Switch to live prices |
Sell:14.80 CAD
Buy:15.57 CAD
Change: 0.20 CAD (1.30%)
Market closed |  Prices as at close on 1 November 2024 | Switch to live prices |
Sell:14.80 CAD
Buy:15.57 CAD
Change: 0.20 CAD (1.30%)
Market closed |  Prices as at close on 1 November 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

Contact details

Address:
5750 Explorer Drive,, Suite 404
MISSISSAUGA
L4W 0A9
Canada
Telephone:
+1 (905) 6025840
Website:
https://www.cipherpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CPH
ISIN:
CA17253X1050
Market cap:
397.59 million CAD
Shares in issue:
25.59 million
Sector:
Pharmaceuticals
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Craig Mull
    Chairman of the Board, Interim Chief Executive Officer
  • Bryan Jacobs
    Chief Financial Officer, Company Secretary
  • Lorne Markowitz
    Vice President of Sales and Marketing
  • Louise Blythe
    Vice President - Regulatory Affairs
  • Lynne Bulger
    Vice President - Medical and Clinical Affairs
  • Michael Milloy
    Vice President - Canadian commercial operations
  • Peter Weiler
    Vice President - Business Development
  • Hamed Ghanei
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.